The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Co-formulated favezelimab plus pembrolizumab versus standard-of-care in previously treated, PD-L1-positive metastatic colorectal cancer: The phase 3, randomized KEYFORM-007 study.
 
Neil Segal
Consulting or Advisory Role - Agenus; AstraZeneca; Novartis; Numab; PureTech; regeneron
Research Funding - Agenus (Inst); AstraZeneca; Bristol-Myers Squibb; Merck; Pfizer; PureTech (Inst); Regeneron (Inst); Roche/Genentech
Travel, Accommodations, Expenses - AstraZeneca/MedImmune; Regeneron
 
Maria Passhak
Honoraria - Merck Serono; Roche
Research Funding - MSD Oncology (Inst)
 
Fatih Köse
Honoraria - Astellas Pharma (Inst); AstraZeneca/Merck (Inst); Deva (Inst); GlaxoSmithKline (Inst); Janssen (Inst); MSD/Merck (Inst); Nobelpharma (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Takeda (Inst)
Consulting or Advisory Role - Astellas Pharma; AstraZeneca/Merck; DevaCell; GlaxoSmithKline; Janssen; MSD/Merck; Nobelpharma; Novartis; Pfizer; Roche; Takeda
 
Eugen Kubala
No Relationships to Disclose
 
Elena Elez
Honoraria - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi/Aventis; Seagan; SERVIER; Takeda
Consulting or Advisory Role - Amgen; Bayer; Boehringer Ingelheim; Bristol Myers Squibb; Cure Teq AG; Janssen; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre Fabre; Repare Therapeutics Inc.; RIN Institute Inc.; Roche; Roche; Sanofi; Seagen; SERVIER; Takeda
Research Funding - Abbvie (Inst); Amgen (Inst); Array BioPharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Bioncotech (Inst); Biontech Rna Pharmaceuticals GMBH (Inst); Biontech Small Molecules GMBH (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim Spain (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Daiichi Sankyo Inc. (Inst); Debiopharm Group (Inst); Genentech (Inst); Gercor (Inst); HalioDx (Inst); Hoffmann-La-Roche Ltd. (Inst); Hutchison MediPharma (Inst); Hutchison MediPharma (Inst); Iovance Biotherapeutics (Inst); Janssen Research & Development (Inst); Janssen-Cilag SA (Inst); MedImmune (Inst); Menarini (Inst); Menarini (Inst); Merck (Inst); Merck Sharp&Dohme de España SA (Inst); Merus NV (Inst); Mirati Therapeutics (Inst); Nouscom SRL. (Inst); Novartis (Inst); Novartis Farmacéutica SA (Inst); Pfizer (Inst); PharmaMar (Inst); Pierre Fabre (Inst); PledPharma (Inst); Redx Pharma (Inst); Roche (Inst); Sanofi (Inst); Scandion Oncology (Inst); Seagen (Inst); SERVIER (Inst); Sotio (Inst); Taiho Pharma USA (Inst); Taiho Pharmaceutical (Inst); WntResearch (Inst)
Travel, Accommodations, Expenses - Amgen; Bayer; Boehringer Ingelheim; Bristol-Myers Squibb; Cure Teq AG; Janssen; Lilly; Medscape; Merck; Merck Serono; MSD; Novartis; Pfizer; Pierre fabre; Repare Therapeutics; RIN Institute Inc.; Roche; Sanofi; Seagan; SERVIER; Takeda
 
Hisato Kawakami
Honoraria - Astellas Pharma; Bristol-Myers Squibb Japan; Chugai/Roche; Daiichi Sankyo; GlaxoSmithKline; Lilly Japan; Merck Serono; MSD K.K; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Pharmaceutical
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb Japan; Daiichi Sankyo Co. Ltd.,; Lilly Japan; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Kobayashi Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Marianne Guren
Research Funding - Merck (Inst)
 
Derek Jonker
Consulting or Advisory Role - AstraZeneca
Research Funding - Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Ocellaris Pharma (Inst); Pfizer (Inst); SeaGen (Inst)
 
Rui-Hua Xu
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; BeiGene; CPPC; Hengrui Pharm; Hutchison MediPharma; Innovent Biologics; Junshi Pharmaceuticals; Keymed Biosience; Merck Serono; MSD; QiLu Pharmaceutical; Roche
 
Jorge Riera
Consulting or Advisory Role - Merck; MSD
Travel, Accommodations, Expenses - Amgen; Novartis
 
Giampaolo Tortora
Consulting or Advisory Role - AstraZeneca; Bristol-Myers Squibb/Celgene; Celgene; Dompé Farmaceutici; Merck Serono; MSD Oncology
Travel, Accommodations, Expenses - Merck Serono; MSD Oncology; Roche
 
Salvatore Siena
Stock and Other Ownership Interests - Guardant Health; Myriad Genetics
Consulting or Advisory Role - Agenus; AstraZeneca; Bayer; Bristol-Myers Squibb; CheckmAb; Daiichi Sankyo; GlaxoSmithKline; Merck; MSD Oncology; Novartis; Pierre Fabre; Pierre Fabre; Seagen; T-One Therapeutics
Research Funding - MSD Oncology (Inst)
Patents, Royalties, Other Intellectual Property - Amgen
Travel, Accommodations, Expenses - Amgen; Bayer; Roche
 
Yu-Min Yeh
Research Funding - Merck (Inst)
 
Mastura Yusof
Research Funding - Merck (Inst)
 
Kai-Keen Shiu
Honoraria - Bayer; Bristol-Myers Squibb; Merck Serono; MSD Oncology; SERVIER
Consulting or Advisory Role - Bristol-Myers Squibb; GlaxoSmithKline; Mirati Therapeutics; MSD Oncology; Nouscom; Roche; Seagen; Takeda
Research Funding - AstraZeneca (Inst); BioNTech SE (Inst); MSD Oncology (Inst); Nouscom (Inst); Roche (Inst)
 
Naureen Starling
Honoraria - Astellas Pharma; AstraZeneca; BMS; BMS; Daiichi Sankyo; GlaxoSmithKline; Merck; Merck Serono; MSD Oncology; MSD Oncology; MSD Oncology; MSD Oncology; Natera; Pierre Fabre; Pierre Fabre; Pierre Fabre; Seagen; SERVIER; SERVIER; SERVIER; Tempus
Consulting or Advisory Role - AstraZeneca; Bristol Myers Squibb; Gilead Sciences; GlaxoSmithKline; Janssen; Moderna Therapeutics; MSD Oncology; Seagen; Takeda
Research Funding - Gilead Sciences (Inst)
Travel, Accommodations, Expenses - Bristol Myers Squibb; GlaxoSmithKline; Guardant Health; MSD Oncology; SERVIER; Takeda
(OPTIONAL) Uncompensated Relationships - Guardant Health
 
Xiang Peng
No Relationships to Disclose
 
David Fogelman
Research Funding - Merck (Inst)
 
David Adelberg
Employment - Merck
Stock and Other Ownership Interests - Merck
Travel, Accommodations, Expenses - Merck
 
Tae Won Kim
Employment - Asan Medical Center
Research Funding - Genome Insight (Inst); Roche/Genentech (Inst)